person · Reporting owner
Myszkowski Kenneth Allen
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Chief Financial Officer | January 04, 2025 | January 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 04, 2025 · Filed January 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500,600 |
Reported balance
After 2025-01-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-04 · Grant · Acquired 100,000 · Balance 500,600 F1: Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments. |
| Common StockSEC Table I · non-derivative | Direct | 482,835 |
Reported balance
After 2025-01-06 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-01-06 · Sale · Disposed 17,765 · Balance 482,835 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.18 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 473,433 |
Reported balance
After 2025-01-06 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-01-06 · Sale · Disposed 9,402 · Balance 473,433 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 465,433 |
Reported balance
After 2025-01-07 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2025-01-07 · Sale · Disposed 8,000 · Balance 465,433 F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.64 to $ 19.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Partial disposition of RSUs to satisfy tax withholding obligations. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Common StockSEC Table I · non-derivative | Direct | 455,433 |
Reported balance
After 2025-01-07 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2025-01-07 · Sale · Disposed 10,000 · Balance 455,433 F8: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.62 to $19.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments.
F2: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3: Partial disposition of RSUs to satisfy tax withholding obligations.
F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.18 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F7: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.64 to $ 19.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F8: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.62 to $19.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2020 Filed Jan 8, 2020 23:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 500 | $60.95 | $30,475.00 |
DisclosureSEC source: 0001209191-20-002613 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,185 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.95 to $61.04, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 11,907 | $60.40 | $719,182.80 |
DisclosureSEC source: 0001209191-20-002613 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,685 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.93 to $60.92, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 7,593 | $59.60 | $452,542.80 |
DisclosureSEC source: 0001209191-20-002613 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,592 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.92 to $59.92, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 22:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001343 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,185 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 12,649 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-19-055735 · doc4.xml · derivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,467 Underlying: Common Stock · 12,649 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 12,649 | $5.19 | $65,648.31 |
DisclosureSEC source: 0001209191-19-055735 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 23:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 37,884 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0001209191-19-054789 · doc4.xml · derivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,116 Underlying: Common Stock · 37,884 shares Expires 2025-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 23:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 16,620 | $41.21 | $684,910.20 |
DisclosureSEC source: 0001209191-19-054789 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,536 F1 · kind: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.01 to $41.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 23:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 21,264 | $40.56 | $862,467.84 |
DisclosureSEC source: 0001209191-19-054789 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,156 F1 · kind: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $41.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 23:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 37,884 | $7.75 | $293,601.00 |
DisclosureSEC source: 0001209191-19-054789 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-19-034038 · doc4.xml · derivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 20,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001209191-19-034038 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 15,000 shares Expires 2021-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 20,000 | $5.19 | $103,800.00 |
DisclosureSEC source: 0001209191-19-034038 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 15,000 | $4.60 | $69,000.00 |
DisclosureSEC source: 0001209191-19-034038 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2019 Filed May 22, 2019 21:44 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 27,071 | $22.00 | $595,562.00 |
DisclosureSEC source: 0001209191-19-032137 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,536 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-19-011831 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 8,000 shares Expires 2020-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,000 | $18.00 | $144,000.00 |
DisclosureSEC source: 0001209191-19-011831 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,607 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 8,000 | $5.20 | $41,600.00 |
DisclosureSEC source: 0001209191-19-011831 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2019 Filed Jan 19, 2019 00:00 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 81,875 | $14.55 | $1,191,281.25 |
DisclosureSEC source: 0001209191-19-004624 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,607 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.28 to $14.72, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,333 | $11.98 | $99,829.34 |
DisclosureSEC source: 0001209191-19-001476 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,482 F2 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.69 to $12.16, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001476 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,815 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · derivative · entry 6 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,000 Underlying: Common Stock · 20,000 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · derivative · entry 5 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,000 Underlying: Common Stock · 25,000 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 20,000 | $21.01 | $420,200.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 25,000 | $18.00 | $450,000.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 20,000 | $4.75 | $95,000.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 22:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 25,000 | $2.62 | $65,500.00 |
DisclosureSEC source: 0001209191-18-050356 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 01:18 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-18-038884 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 01:18 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 20,000 | $14.01 | $280,200.00 |
DisclosureSEC source: 0001209191-18-038884 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 01:18 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 20,000 | $2.01 | $40,200.00 |
DisclosureSEC source: 0001209191-18-038884 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 21:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 12,600 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · derivative · entry 6 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,000 Underlying: Common Stock · 12,600 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 21:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 12,600 | $11.00 | $138,600.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · nonDerivative · entry 4 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 21:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 12,600 | $2.01 | $25,326.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · nonDerivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · derivative · entry 5 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,600 Underlying: Common Stock · 1,400 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,400 | $11.00 | $15,400.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:34 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 1,400 | $2.01 | $2,814.00 |
DisclosureSEC source: 0001209191-18-034785 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 23:46 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-18-021843 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 23:46 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 20,000 | $8.00 | $160,000.00 |
DisclosureSEC source: 0001209191-18-021843 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| March 27, 2018 Filed Mar 27, 2018 23:46 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 20,000 | $2.01 | $40,200.00 |
DisclosureSEC source: 0001209191-18-021843 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 01:46 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Tax withholdingCommon Stock | 8,208 | $6.66 | $54,665.28 |
DisclosureSEC source: 0001209191-18-016992 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,815 F1 · kind: This transaction reflects the payment of the tax liability by withholding securities incident to the vesting of restricted stock units on 03/05/2018. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:28 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001480 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,023 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| June 08, 2017 Filed Oct 6, 2017 20:14 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056291 · doc5.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,023 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 01:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 145,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001607 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,689 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment in January 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.